Leukine
information and resources from the National Cancer Institute
Leukine
(Other name for: sargramostim)leuprolide acetate
The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. Leukine
(Other name for: sargramostim)
|
|
|
|
news articles
FDA Approvals: Aranesp, Taxotere, Leukine Mar 28, 2006
Medscape (subscription) The FDA approved in January a new formulation for sargramostrim 500 µg/mL liquid injection (Leukine, made by Berlex Oncology, a unit of Berlex Laboratories ...
Less talk, more action Mar 20, 2006
Bizjournals.com, As it stands, Leukine, a cancer-care drug made by Berlex Laboratories, is the only bulk drug with a made-in-Washington label. Berlex ...
Bayer Makes Move To Buy Schering AG Mar 25, 2006
Medical News Today (press release), The products in this area include Schering's top-selling Betaseron® for the treatment of multiple sclerosis and Leukine®, used to boost a patient's immune ...
Schering Accepts Bayer's EUR 16.3 Bln Cash Takeover Offer, To Form ... Mar 23, 2006
Trading Markets, The products in this area include Schering's top-selling Betaseron for the treatment of multiple sclerosis and Leukine, used to boost a patient's immune system ...
Address by Werner Wenning Mar 24, 2006
PharmaLive.com (press release), These include the top-selling Schering drug Betaseron ® and two other growth drivers: Schering's Leukine ® and Bayer's Kogenate ® , which also has ...
Schering Cuts Angeliq Sales Forecast; Shares Fall (Update1) Mar 10, 2006
Bloomberg The company also delayed seeking approval for Leukine to treat Crohn's disease, stopped an advanced trial on Asoprisnil for benign uterine tumors, and said ...
German Pharma Powerhouse Potential Mar 13, 2006
BusinessWeek ...cancer. Schering brings its blood-cancer drugs Leukine and Campath to the table. Merck would also gain access to new markets. Schering ...
Manhattan Research Reveals Top Ten Consumer-Ranked Pharmaceutical ... Mar 7, 2006
PR Newswire (press release), XR, Elidel, Enbrel, Evista, Femara, Flonase, Flovent, Fosamax, Glucophage XR, Herceptin, Humalog, Humira, Humulin, Imitrex, Lamisil, Leukine, Levaquin, Levitra ...
New Data Suggest GM-CSF May Enhance Efficacy of Rituximab in ... Dec 12, 2005
PR Newswire (press release), Data from a similar study presented earlier this year demonstrated that the GM-CSF Leukine(R) appeared to improve the efficacy of rituximab in treating the ...
New Data Suggest Novel Low-dose Outpatient Chemobiotherapy Regimen ... Dec 12, 2005
PharmaLive.com (press release), A novel low-dose outpatient chemobiotherapy combination of temozolomide, the granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R) (sargramostim ...
Schering May Have to Pay to Protect Betaseron (Update1) Dec 9, 2005
Bloomberg The company also delayed seeking approval for Leukine to treat Crohn's disease, stopped an advanced trial on Asoprisnil to treat benign uterine tumors, and ...
Schering CEO sees continued growth, sticks to 2006 18 pct opg ... Nov 29, 2005
Forbes As an example, he mentioned the licensed-in drug Leukine (to treat Crohn's disease) with current sales of 60 mln, but with a sales potential of 250 mln eur ...
Schering Chief Sees Blockbuster Potential for Cancer Drug Nov 30, 2005
Bloomberg Schering this year has delayed seeking approval for Leukine to treat Crohn's disease, stopped an advanced clinical trial on Asoprisnil to treat benign uterine ...
|
|
